Clinical Trial: Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188740) titled 'Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia' on Sept. 16.

Brief Summary: This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under follow-up. Patients with DNMT3A R882 mutation (VAF >=5%) will receive oral metformin for 6 months, with dosage gradually increased to 2000 mg/day. The primary endpoint is the proportion of patients with effective decline in DNMT3A R882 mutation VAF at 6 months. Secondary endpoints include VAF decline at 3 months, relaps...